MORRIS, MANNING & MARTIN, LLP ATTORNEYS AT LAW

RECEIVED CENTRAL FAX CENTER

FACSIMILE TRANSMISSION **FORM**

1600 Atlanta Financial Center 3343 Peachtree Road. N.E. Atlanta, Georgia 30326

OCT 3 1 2006

Facsimile Number: 404-365-9532

This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via U.S. Postal Service. Thank you.

TO:

United States Patent & Trademark Office

Mail Stop AF

DATE & TIME:

October 31, 2006

TOTAL PAGES:

5 (Includes Fax Cover)

FAX NUMBER:

571-273-8300

FROM: Morris, Manning & Martin, LLP

CHARGE TO: 14507-47022

NAME: Hsiu-Ming Saunders, Esq.

PHONE: (404) 233-7000

CONFIRMATION TIME:

SEC MIN

COMMENTS:

Application No.: 10/699,393

Attorney Docket No. 14507-47022

Filing Date: October 31, 2003

I hereby certify that the attached documents are being sent via facsimile to the USPTO this 31st day of October, 2006:

Transmittal Sheet containing Certificate of Facsimile (1 page)

Statement of the Substance of the Interview (3 pages)

RECEIVED CENTRAL FAX CENTER

S/N 10/699,393

OCT 3 1 2006

PATENT Confirmation No. 3913

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Gruber, et al.

Examiner:

Swope, Sheridan L.

Serial No.:

10/699,393

Group Art Unit:

1652

Filed:

October 31, 2003

Docket No.:

14507-47022

Title:

Anti-Thrombotic Thrombin Variants

CERTIFICATE UNDER 37 CFR 1.8(a):

Thereby certify that this correspondence is being transmitted by facsimile to number 571-273-8300 addressed to Mail Stop: AF, Commissioner for Patents, United States Patent and Trademark Office on October 31, 2006.

TRANSMITTAL

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 October 31, 2006

CUSTOMER NO. 24728

Sir:

We are transmitting herewith the attached:

▼ Transmittal Sheet containing Certificate of Facsimile (1 page)

Statement of the Substance of the Interview (3 pages)

MORRIS, MANNING & MARTIN, LLP 1600 Atlanta Financial Center 3343 Peachtree Road NE Atlanta, Georgia 30326 404.504.7688 Customer No. 24728

Name: Hsiu-Ming Säunder

Reg. No.: 47,055

4043644578

P.003/005 T-107

RECEIVED CENTRAL FAX CENTER

S/N 10/699,393

OCT 3 1 2006

Patent

Conformation No. 3913

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Gruber, Andras et al.

Examiner:

Swope, Sheridan L.

Serial No.:

10/699,393

Group Art Unit:

1652

Filed:

October 31, 2003

Docket No.:

14507-47022

(Formerly E056 1071.1)

Title:

Anti-Thrombotic Thrombin Variants

CERTIFICATE UNDER 37 CFR 1.8(a);

I hereby certify that this correspondence is being transmitted by facsimile to number 571-273-8300 addressed to Mail

Stop: AF, Commissioner for Patents, United States Patent and Trademark Office on October 31, 2006.

STATEMENT OF THE SUBSTANCE OF THE INTERVIEW

Mail Stop: AF

Commissioner of Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

October 31, 2006

CUSTOMER NO. 24728

Dear Sir:

In response to the Office Communication mailed October 23, 2006, submitted herewith is a statement of the substance of the interview conducted on October 11, 2006.

Record of Interview begins on page 2 of this paper.

(-31-2000 09:00am Fichi-morri

Application No. 10/699,393
Response Dated October 31, 2006
Reply to Office Communication of October 23, 2006

RECORD OF INTERVIEW

Applicants through the attorney on the record and identified below thank the Examiner Sheridan L. Swope for the time spent in having a telephone interview with Applicants on October 11, 2006.

Pursuant to 37 C.F.R. § 1.133(b), the following is submitted as a complete written statement of the reasons presented at the interview as warranting favorable action. The following statement is intended to comply with the requirements of MPEP § 713.04 and expressly sets forth: (A) a brief description of the nature any exhibit shown or any demonstration conducted; (B) identification of the claims discussed; (C) identification of specific prior art discussed; (D) identification of the principal proposed amendments of a substantive nature discussed; (E) the general thrust of the principal arguments; (F) a general indication of any other pertinent matters; and (G) the general results or outcome of the interview, if appropriate.

On October 11, 2006, the undersigned contacted the examiner to discuss the Office

Action of August 24, 2006. (A) no exhibits were shown or discussed; (B) the independent claim

1 was discussed; (C) no specific prior art is discussed; (D) the possible amendments to overcome

§112, first paragraph rejections were discussed; (E) questions were raised about the Examiner's

points on the motivation under §103 and the unexpected property of the invention; (F) no other

matters were discussed; and (G) the examiner indicated that she would not get into a debate with

Applicants then but suggested the Applicants to do their best in submitting a response to the

Office Action and she would try her best to help Applicants.

Application No. 10/699,393 Response Dated October 31, 2006 Reply to Office Communication of October 23, 2006

In the event that the foregoing record is not considered complete and accurate, the Examiner is respectfully requested to bring any incompleteness or inaccuracy to the attention of the undersigned.

Respectfully submitted,
MORRIS, MANNING & MARTIN, LLP

October 31, 2006

Hsiu-Ming Saunders, Ph.D., J.D.

Reg. No. 47,055

MORRIS, MANNING & MARTIN, LLP 1600 Atlanta Financial Center 3343 Peachtree Road, N.E. Atlanta, Georgia 30326-1044

Phone: 404-233-7000

Direct: 404-504-7688

Customer No. 24728